CSL Total Current Liabilities 2017-2024 | CSLLY

CSL total current liabilities for the quarter ending June 30, 2024 were $4.950B, a 96.11% increase year-over-year.

  • CSL total current liabilities for 2024 were $4.95B, a 7.42% increase from 2023.
  • CSL total current liabilities for 2023 were $4.608B, a 35.17% decline from 2022.
  • CSL total current liabilities for 2022 were $7.108B, a 129.02% increase from 2021.

CSL Total Current Liabilities 2017-2024 | CSLLY

  • CSL total current liabilities for 2024 were $4.95B, a 7.42% increase from 2023.
  • CSL total current liabilities for 2023 were $4.608B, a 35.17% decline from 2022.
  • CSL total current liabilities for 2022 were $7.108B, a 129.02% increase from 2021.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158.3B
Bristol Myers Squibb (BMY)$119.4B
Vertex Pharmaceuticals (VRTX)$116.1B
Gilead Sciences (GILD)$112.4B
Regeneron Pharmaceuticals (REGN)$81.1B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$31.6B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$23B
Illumina (ILMN)$22.2B
BeiGene (BGNE)$18.6B
Moderna (MRNA)$15.8B
Incyte (INCY)$13.8B
Genmab (GMAB)$13.7B
Insmed (INSM)$13.1B
BioMarin Pharmaceutical (BMRN)$12.2B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.9B
Legend Biotech (LEGN)$7.5B